NEO · Neogenomics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $105.81M | - | $107.35M | $104.07M | $94.79M | - | $92.94M | $92.01M | $90.77M | - |
| Gross Profit | $80.86M | - | $80.45M | $77.26M | $73.25M | - | $74.88M | $72.49M | $65.47M | - |
| R&D | $9.53M | - | $8.69M | $9.02M | $10.18M | - | $7.68M | $7.89M | $7.62M | - |
| SG&A | $65.74M | - | $69.87M | $71.75M | $68.21M | - | $66.97M | $63.33M | $65.80M | - |
| Total Operating Expenses | $99.11M | - | $107.46M | $124.89M | $101.07M | - | $96.08M | $94.44M | $96.04M | - |
| D&A | $8.78M | - | - | - | $9.37M | - | - | - | $9.90M | - |
| Operating Income | ($18.24M) | - | ($27.01M) | ($47.63M) | ($27.82M) | - | ($21.20M) | ($21.94M) | ($30.57M) | - |
| Interest Expense | $598.0K | - | $603.0K | $933.0K | $1.69M | - | $1.64M | $1.67M | $1.69M | - |
| Income Tax | ($472.0K) | - | $740.0K | ($724.0K) | $266.0K | - | ($150.0K) | ($375.0K) | ($620.0K) | - |
| Net Income | ($17.11M) | - | ($27.13M) | ($45.09M) | ($25.92M) | - | ($17.70M) | ($18.64M) | ($27.06M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $146.14M | $159.62M | $164.12M | $154.72M | $346.19M | $367.01M | $361.99M | $355.08M | $331.91M | $342.49M |
| Accounts Receivable | $167.42M | $159.24M | $155.30M | $153.13M | $151.21M | $150.54M | $151.43M | $146.58M | $140.28M | $131.23M |
| Inventory | $29.84M | $28.57M | $28.46M | $34.17M | $29.77M | $26.75M | $24.46M | $23.21M | $20.32M | $24.16M |
| Accounts Payable | $25.90M | $23.09M | $22.61M | $27.49M | $16.21M | $21.61M | $16.51M | $17.19M | $18.34M | $20.33M |
| Current Assets | $373.68M | $376.29M | $382.46M | $392.55M | $573.93M | $596.02M | $590.24M | $584.20M | $573.90M | $596.81M |
| Total Assets | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B | $1.64B | $1.64B | $1.64B | $1.68B |
| Current Liabilities | $84.59M | $88.30M | $97.87M | $100.12M | $279.69M | $301.24M | $296.41M | $289.96M | $76.71M | $96.30M |
| Long-term Debt | - | $341.86M | - | - | - | $340.33M | - | - | - | $538.20M |
| Total Liabilities | $517.77M | $523.27M | $536.49M | $539.91M | $713.16M | $735.70M | $732.90M | $727.39M | $716.93M | $739.69M |
| Stockholders' Equity | $828.76M | $836.56M | $838.29M | $854.04M | $888.27M | $902.34M | $908.21M | $915.88M | $923.41M | $941.54M |
| Retained Earnings | ($450.91M) | ($433.81M) | ($423.93M) | ($396.80M) | ($351.70M) | ($325.78M) | ($310.46M) | ($292.76M) | ($274.12M) | ($247.06M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.14M) | - | - | - | ($25.33M) | - | - | - | ($25.91M) | - |
| Investing Cash Flow | ($5.00M) | - | - | - | $3.56M | - | - | - | $14.53M | - |
| Financing Cash Flow | ($338.0K) | - | - | - | $949.0K | - | - | - | $816.0K | - |
| CapEx | $5.00M | - | - | - | $4.50M | - | - | - | $5.58M | - |
| Free Cash Flow | ($13.14M) | - | - | - | ($29.83M) | - | - | - | ($31.50M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.77 | - | - | - | 1.15 | - | - | - | 1.16 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -1.3% | - | -2.0% | -3.2% | -1.6% | - | -1.1% | -1.1% | -1.6% | - |
| Return on equity | -2.1% | - | -3.2% | -5.3% | -2.9% | - | -1.9% | -2.0% | -2.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.42 | 4.26 | 3.91 | 3.92 | 2.05 | 1.98 | 1.99 | 2.01 | 7.48 | 6.20 |
| Quick ratio | 4.06 | 3.94 | 3.62 | 3.58 | 1.95 | 1.89 | 1.91 | 1.93 | 7.22 | 5.95 |
| Cash ratio | 1.73 | 1.81 | 1.68 | 1.55 | 1.24 | 1.22 | 1.22 | 1.22 | 4.33 | 3.56 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.41 | - | - | - | 0.38 | - | - | - | 0.57 |
| Debt / Assets | - | 0.25 | - | - | - | 0.21 | - | - | - | 0.32 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -30.5x | - | -44.8x | -51.0x | -16.5x | - | -12.9x | -13.2x | -18.1x | - |
| Equity multiplier | 1.62 | 1.63 | 1.64 | 1.63 | 1.80 | 1.82 | 1.81 | 1.79 | 1.78 | 1.79 |
| Liabilities / Assets | 0.38 | 0.38 | 0.39 | 0.39 | 0.45 | 0.45 | 0.45 | 0.44 | 0.44 | 0.44 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 3.55 | - | 3.77 | 3.05 | 3.18 | - | 3.80 | 3.96 | 4.47 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 103d | - | 97d | 120d | 115d | - | 96d | 92d | 82d | - |
| Days payable outstanding | 89d | - | 77d | 96d | 62d | - | 65d | 68d | 74d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.2x | - | 1.2x | 1.1x | 1.4x | - | 2.1x | 1.9x | 2.1x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 10.4% | - | 7.4% | 6.6% | 11.9% | - | 20.2% | 21.0% | 19.4% | - |
| Operating income growth (YoY) | 34.4% | - | -27.4% | -117.1% | 9.0% | - | 12.4% | 26.6% | 12.8% | - |
| Net income growth (YoY) | 34.0% | - | -53.3% | -141.9% | 4.2% | - | 4.4% | 23.4% | 12.1% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 56.0% | - | - | - | 5.3% | - | - | - | -39.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -6.7% | -7.3% | -7.7% | -6.8% | -3.8% | -4.2% | -4.1% | -4.2% | -5.2% | -5.7% |
Peer comparison
Same SIC group: Services-Testing Laboratories
Comparing NEOGENOMICS INC against the 4 most active filers in the same SIC group.